Site icon Market Globalist

Here’s to why Xeris Pharmaceuticals Inc. (XERS) stock plunge during current market?

TDOC Stock

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) stock declines by 19.00% in the current market trading. Xeris is a specialized pharmaceutical business that develops cutting-edge technologies to make providing critical medicines easier for individuals all around the world.

>> 7 Top Picks for the Post-Pandemic Economy << 

XERS stock, Financial Highlights

Xeris Pharmaceuticals announced its second-quarter 2021 financial results. Given below is the summary:

Read More

Paul R. Edick, Chairman, and CEO of Xeris stated,

Given the ongoing challenges posed by the worldwide pandemic, they are happy with their stable, constantly rising financial results in the first quarter. Despite a depressed market, Gvoke demand rose, Ogluo was approved in the EU and UK, and their conversations with the FDA clarified their planned Phase 3 trial designs. The progress has continued into the second quarter, and they are pleased by what looks to be improved consistency in the endocrinology industry in general and the glucagon market in particular.

Exit mobile version